Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.
2.

Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.

Li QX, Villemagne VL, Doecke JD, Rembach A, Sarros S, Varghese S, McGlade A, Laughton KM, Pertile KK, Fowler CJ, Rumble RL, Trounson BO, Taddei K, Rainey-Smith SR, Laws SM, Robertson JS, Evered LA, Silbert B, Ellis KA, Rowe CC, Macaulay SL, Darby D, Martins RN, Ames D, Masters CL, Collins S; AIBL Research Group.

J Alzheimers Dis. 2015;48(1):175-87. doi: 10.3233/JAD-150247.

PMID:
26401938
3.

High PIB retention in Alzheimer's disease is an early event with complex relationship with CSF biomarkers and functional parameters.

Forsberg A, Almkvist O, Engler H, Wall A, Långström B, Nordberg A.

Curr Alzheimer Res. 2010 Feb;7(1):56-66.

PMID:
20205671
4.

Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease.

Kadir A, Marutle A, Gonzalez D, Schöll M, Almkvist O, Mousavi M, Mustafiz T, Darreh-Shori T, Nennesmo I, Nordberg A.

Brain. 2011 Jan;134(Pt 1):301-17. doi: 10.1093/brain/awq349. Epub 2010 Dec 13.

5.

Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology.

Laforce R Jr, Tosun D, Ghosh P, Lehmann M, Madison CM, Weiner MW, Miller BL, Jagust WJ, Rabinovici GD.

Neuroimage Clin. 2014 Mar 19;4:508-16. doi: 10.1016/j.nicl.2014.03.005. eCollection 2014.

6.

Core candidate neurochemical and imaging biomarkers of Alzheimer's disease.

Hampel H, Bürger K, Teipel SJ, Bokde AL, Zetterberg H, Blennow K.

Alzheimers Dement. 2008 Jan;4(1):38-48. doi: 10.1016/j.jalz.2007.08.006. Epub 2007 Dec 21. Review.

PMID:
18631949
7.

Cognitive and Brain Profiles Associated with Current Neuroimaging Biomarkers of Preclinical Alzheimer's Disease.

Besson FL, La Joie R, Doeuvre L, Gaubert M, Mézenge F, Egret S, Landeau B, Barré L, Abbas A, Ibazizene M, de La Sayette V, Desgranges B, Eustache F, Chételat G.

J Neurosci. 2015 Jul 22;35(29):10402-11. doi: 10.1523/JNEUROSCI.0150-15.2015.

8.

Molecular imaging of dementia.

Mori T, Maeda J, Shimada H, Higuchi M, Shinotoh H, Ueno S, Suhara T.

Psychogeriatrics. 2012 Jun;12(2):106-14. doi: 10.1111/j.1479-8301.2012.00409.x. Review.

9.

Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease.

Jack CR Jr, Wiste HJ, Vemuri P, Weigand SD, Senjem ML, Zeng G, Bernstein MA, Gunter JL, Pankratz VS, Aisen PS, Weiner MW, Petersen RC, Shaw LM, Trojanowski JQ, Knopman DS; Alzheimer's Disease Neuroimaging Initiative.

Brain. 2010 Nov;133(11):3336-48. doi: 10.1093/brain/awq277. Epub 2010 Oct 8.

10.

Amyloid imaging in Alzheimer's disease and other dementias.

Fodero-Tavoletti MT, Cappai R, McLean CA, Pike KE, Adlard PA, Cowie T, Connor AR, Masters CL, Rowe CC, Villemagne VL.

Brain Imaging Behav. 2009 Sep;3(3):246-61. doi: 10.1007/s11682-009-9067-2. Epub 2009 Apr 7.

PMID:
22005989
11.

Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease.

Kerbler GM, Fripp J, Rowe CC, Villemagne VL, Salvado O, Rose S, Coulson EJ; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage Clin. 2014 Nov 27;7:105-13. doi: 10.1016/j.nicl.2014.11.015. eCollection 2015.

12.

Amyloid biomarkers in Alzheimer's disease.

Blennow K, Mattsson N, Schöll M, Hansson O, Zetterberg H.

Trends Pharmacol Sci. 2015 May;36(5):297-309. doi: 10.1016/j.tips.2015.03.002. Epub 2015 Apr 1. Review.

PMID:
25840462
13.

Alzheimer's disease.

De-Paula VJ, Radanovic M, Diniz BS, Forlenza OV.

Subcell Biochem. 2012;65:329-52. doi: 10.1007/978-94-007-5416-4_14. Review.

PMID:
23225010
14.

Long night's journey into the day: amyloid-β imaging in Alzheimer's disease.

Villemagne VL, Rowe CC.

J Alzheimers Dis. 2013;33 Suppl 1:S349-59. Review.

PMID:
22710919
15.

The dynamic marker hypothesis of Alzheimer's disease and its implications for clinical imaging.

Cavedo E, Frisoni GB.

Q J Nucl Med Mol Imaging. 2011 Jun;55(3):237-49. Review.

PMID:
21532538
16.

Amyloid tracers detect multiple binding sites in Alzheimer's disease brain tissue.

Ni R, Gillberg PG, Bergfors A, Marutle A, Nordberg A.

Brain. 2013 Jul;136(Pt 7):2217-27. doi: 10.1093/brain/awt142. Epub 2013 Jun 11.

PMID:
23757761
17.

Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies.

Chen Z, Zhong C.

Prog Neurobiol. 2013 Sep;108:21-43. doi: 10.1016/j.pneurobio.2013.06.004. Epub 2013 Jul 11. Review.

18.

Amyloid imaging.

Villemagne VL, Rowe CC.

Int Psychogeriatr. 2011 Sep;23 Suppl 2:S41-9. doi: 10.1017/S1041610211000895. Review.

PMID:
21729418
19.

Integrating ADNI results into Alzheimer's disease drug development programs.

Cummings JL.

Neurobiol Aging. 2010 Aug;31(8):1481-92. doi: 10.1016/j.neurobiolaging.2010.03.016. Epub 2010 May 5. Review.

20.

Amyloid imaging for Alzheimer's disease.

Kerchner GA.

Expert Opin Med Diagn. 2011 Nov;5(6):527-38. doi: 10.1517/17530059.2011.617365. Epub 2011 Oct 18.

PMID:
23484750

Supplemental Content

Support Center